<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">8398707</article-id><article-id pub-id-type="pmc">1968602</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Masuda</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fukuoka</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kudoh</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kusunoki</surname><given-names>Y.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Matsui</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Takifuji</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nakagawa</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tamanoi</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nitta</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hirashima</surname><given-names>T.</given-names></name></contrib><etal/></contrib-group><aff>Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Osaka, Japan.</aff><pub-date pub-type="ppub"><month>10</month><year>1993</year></pub-date><volume>68</volume><issue>4</issue><fpage>777</fpage><lpage>782</lpage><abstract><p>We have conducted a Phase I trial to determine the maximum tolerated dose of CPT-11 together with a fixed dose of cisplatin in patients with advanced lung cancer, and the dose-limiting toxicities of this combination. Fourteen previously untreated patients with stage IIIB or IV disease were treated with CPT-11 (90-min intravenous infusion on days 1, 8, and 15) plus cisplatin (60 mg m-2, intravenously on day 1). The starting dose of CPT-11 was 60 mg m-2, and diarrhea was the dose-limiting toxicity at the 90 mg m-2 dose level. All three patients (all four cycles) given 90 mg m-2 of CPT-11 experienced grade 3 diarrhea. Hematologic toxicity was relatively mild. Elimination of CPT-11 was biphasic with a mean (+/- s.d.) beta half-life of 11.36 +/- 7.26 h. The mean terminal half-life of the major metabolite (7-ethyl-10-hydroxycamptothecin; SN-38) was 22.13 +/- 13.28 (s.d.) h, and modest escalation of the CPT-11 dose from 80 mg m-2 to 90 mg m-2 resulted in a statistically significant apparent increase in the plasma concentrations of SN-38. There were one complete response (7%) and five partial responses (36%) among the 14 patients for an overall response rate of 43%. The recommended dose for Phase II studies is 80 mg m-2 of CPT-11 and 60 mg m-2 of cisplatin.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00200-0133.tif" xlink:title="scanned-page" xlink:role="777" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00200-0134.tif" xlink:title="scanned-page" xlink:role="778" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00200-0135.tif" xlink:title="scanned-page" xlink:role="779" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00200-0136.tif" xlink:title="scanned-page" xlink:role="780" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00200-0137.tif" xlink:title="scanned-page" xlink:role="781" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00200-0138.tif" xlink:title="scanned-page" xlink:role="782" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

